Intellia Therapeutics - Stock Price History | NTLA
Historical daily share price chart and data for Intellia Therapeutics since 2021 adjusted for splits. The latest closing stock price for Intellia Therapeutics as of September 27, 2021 is 147.58.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
- The all-time high Intellia Therapeutics stock closing price was 176.78 on September 03, 2021.
- The Intellia Therapeutics 52-week high stock price is 202.73, which is 37.4% above the current share price.
- The Intellia Therapeutics 52-week low stock price is 18.81, which is 87.3% below the current share price.
- The average Intellia Therapeutics stock price for the last 52 weeks is 82.49.
|Intellia Therapeutics Historical Annual Stock Price Data
||Average Stock Price
||Annual % Change
||Medical - Biomedical and Genetics
Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia's combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products.